中文名：重组人骨髓基质蛋白9
Characteristics:
Source HEK 293
Description Human BMP-9 (Ser320-Arg429) Accession # Q9UK05
Predicted molecular 12.1 kDa (monomer)
Mass
Specification:
Appearance White powder,Colorless clear liquid after reconstitution
Purity ≥95%, by SDS-PAGE (under reducing (R)&Non-reducing conditions,
visualized by Coomassie staining)
visualized by Coomassie staining)
Endotoxin ≤10 EU/mg by the LAL method
Activity Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells.
The expected ED50 for this effect is ＜2.0 ng/ml.
Formulation Lyophilized from a 0.22 um filtered solution containing 0.085% TFA,30% ACN,5% Mannitol, pH 2.5
Handling and Storage:
Reconstitution It is recommended to redissolve in 4mM HCl
Shipping The product is shipped with blue ice.
Storage & Stability 36 months at -20°C to -80°C in lyophilized state6 months at -20°C to -80°C under sterile
conditions after reconstitution 7-10 days at 2°C to 8°C under sterile conditions after reconstitutionUse
a manualdefrost freezer and avoid repeated freeze-thaw cycles.
Bioactivity:
.jpg)
Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected ED50 for this effect is < 2.0 ng/ml. The activity of recombinant Human BMP9 (Cat. No. mly10801) is higher than the other competing product.
Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected ED50 for this effect is < 2.0 ng/ml. The activity of recombinant Human BMP9 (Cat. No. mly10801) is higher than the other competing product.
